



## **Combined Ordinary and Extraordinary General Meeting on June 29<sup>th</sup> 2011**

### Procedures for obtaining preparatory documents

**Paris, May 25<sup>th</sup> 2011** – BioAlliance Pharma's shareholders are invited to attend the Combined Ordinary and Extraordinary General Meeting to be held at 2.00 pm on June 29<sup>th</sup> 2011 at the company's head office (49 Boulevard du Général Martial Valin, F-75015 Paris, France).

The official notice of the Meeting will be published in the French Republic's Bulletin des Annonces Légales Obligatoires ("Bulletin of Mandatory Legal Announcements") dated May 25<sup>th</sup> 2011 and contains the agenda, the draft resolutions and information on attendance and voting procedures. It can be viewed on the company's web site at:

<http://www.bioalliancepharma.com/eng/Investisseurs/Shareholders-Meetings>

Notice of the meeting will also be published in an official journal of legal announcements on June 13<sup>th</sup> 2011.

Documents related to the meeting will be made available to shareholders, under the conditions set out in the current legislation, and will also be posted on the company's website at [www.bioalliancepharma.com](http://www.bioalliancepharma.com) from June 13<sup>th</sup> 2011 onwards.

Shareholders may, in accordance with Articles R.225-88 and R.225-89 of the French Commercial Code, consult the afore-mentioned documents (together with the information specified in Articles R.225-81 and R.225-83 of the said Code) at the company's head office or request supply of the said documents and information by post/mail to a duly indicated postal/mailling or electronic address by writing to BioAlliance Pharma (Direction Financière – 49 boulevard du Général Martial Valin, F-75015 Paris, France), faxing to +33 1 45 58 08 81 or sending an e-mail to [ag2011@bioalliancepharma.com](mailto:ag2011@bioalliancepharma.com) from June 13<sup>th</sup> 2011 onwards.

## **About BioAlliance Pharma**

Dedicated to cancer and supportive care treatment with a focus on resistance targeting and orphan products — BioAlliance conceives and develops innovative products, for specialty markets especially in the hospital setting and for orphan or rare diseases.

Created in 1997 and introduced to the Euronext Paris market in 2005, BioAlliance Pharma's ambition is to become a leading player in these fields by coupling innovation to patient needs. The company's teams have the key competencies required to identify, develop and register drugs in Europe and the USA; the products' commercialization rights are licensed to international commercial partners invested in the hospital setting. In areas where medical needs are insufficiently met, its targeted approaches help overcome drug resistance and improve patient health & quality of life.

BioAlliance Pharma has developed an advanced product portfolio:

### **Specialty products**

Loramyc®/Oravig® (oropharyngeal candidiasis in immunocompromised patients): Registered in 28 countries (EU US, Korea)

Setofilm® (prevention and treatment of nausea and vomiting post chemo-radiotherapy and post operative) - Registered in EU

Sitavir®/Acyclovir Lauriad™ (labialis herpes): Positive phase III final results; registration status

Fentanyl Lauriad™ (chronic cancer pain): Positive preliminary Phase I results

### **Orphan Oncology products**

Livatag® (Doxorubicin Transdrug™) in primary liver cancer: Phase II results on survival

Clonidine Lauriad™ (mucositis): Phase II on going

AMEP® (invasive melanoma): Phase I on going

For more information, visit the BioAlliance Pharma web site at [www.bioalliancepharma.com](http://www.bioalliancepharma.com)

## **Disclaimer**

*This communication expressly or implicitly contains certain forward-looking statements concerning BioAlliance Pharma SA and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of BioAlliance Pharma SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. BioAlliance Pharma SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.*

*For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of BioAlliance Pharma SA to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the 2009 Reference Document filed with the AMF on June 29, 2010, which is available on the AMF website (<http://www.amf-france.org>) or on BioAlliance Pharma SA's website (<http://www.bioalliancepharma.com>).*

### **BioAlliance Pharma SA**

Dominique Costantini, CEO

Tel.: +33 1 45 58 76 01

[dominique.costantini@bioalliancepharma.com](mailto:dominique.costantini@bioalliancepharma.com)

Judith Greciet, COO

Tel +33 1 45 58 70 61

[judith.greciet@bioalliancepharma.com](mailto:judith.greciet@bioalliancepharma.com)

Nicolas Fellmann, CFO

Tel.: +33 1 45 58 71 00

[nicolas.fellmann@bioalliancepharma.com](mailto:nicolas.fellmann@bioalliancepharma.com)

### **ALIZE RP**

Caroline Carmagnol

Tel.: +33 6 64 18 99 59

[caroline@alizerp.com](mailto:caroline@alizerp.com)